Imaging cancer-associated fibroblasts in localized pancreatic cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II trial evaluates the effectiveness of 68Ga-FAPI-46 PET/CT scans in detecting cancer-associated fibroblasts (CAFs) in patients with localized pancreatic ductal adenocarcinoma (PDA). The study aims to determine the sensitivity and specificity of this imaging technique and to develop a model predicting surgical outcomes based on PET biomarkers. Patients will receive an intravenous injection of 68Ga-FAPI-46, followed by PET/CT scans at baseline and during follow-up visits. The trial will track patient outcomes for five years after treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults \> 18 years (yrs.) with treatment-naive biopsy-proven PDA or with findings diagnostic for PDA on baseline imaging (CT, MRI, or PET)
* Localized disease expected to undergo surgical resection following neoadjuvant therapy (NAT)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Ability to provide informed consent

Exclusion Criteria:

* Hypersensitivity to any excipients in 68Ga-FAPI-46
* Require emergency surgery
* Non-PDA histology on biopsy
* Histopathologically proven metastatic PDA
* Pregnant or lactating women

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Ajit H. Goenka, M.D. — Mayo Clinic in Rochester

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Brief telehealth psychological support during pre-surgery (neoadjuvant) treatment for localized pancreatic cancer

  We will try weekly 40-minute telehealth sessions with a psychologist to reduce stress and improve quality of life for people with localized pancreatic cancer receiving neoadjuvant chemotherapy or radiation.

  Recruiting Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07124611

• Exploring how diet and gut bacteria affect chemotherapy response in pancreatic cancer

  This study is testing how diet and gut bacteria affect how well people with pancreatic cancer respond to chemotherapy.

  Recruiting Emory University · Atlanta, Georgia · NCT06595160

• SMAD4-tailored neoadjuvant therapy for pancreatic cancer that can be surgically removed

  This trial tests whether using SMAD4 mutation status can guide pre-surgery chemotherapy for patients with resectable or borderline resectable pancreatic ductal adenocarcinoma.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT07748611

• A tailored web program to boost exercise and healthy eating for pancreatic cancer patients before surgery

  This trial tests a personalized web portal called COMPASS to help adults with stage I–III pancreatic cancer who are receiving neoadjuvant chemotherapy to improve exercise and dietary habits.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT07651358

• Samuraciclib given before surgery or chemotherapy for certain pancreatic cancers

  This study tests whether taking samuraciclib before standard treatment is safe and helps patients with localized pancreatic cancer.

  Recruiting Phase 1 University of Washington · Seattle, Washington · NCT07645651

• Tumor DNA and protein testing to understand pancreatic cancer treatment response

  This trial will test whether measuring tumor DNA and proteins from people with resectable or locally advanced pancreatic ductal adenocarcinoma can be done quickly enough and provide information about how their cancer responds to standard chemotherapy.

  Recruiting British Columbia Cancer Agency · Vancouver, British Columbia · NCT06574620

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.